利拉格卢提德通过减少粉样β积累和抑制5 × FAD小鼠的炎症来改善认知功能
Liqin Qi1, Lijing Lin1, Jiaping Zheng1
1Department of Endocrinology, Fujian Institute of Endocrinology, Fujian Medical University Union Hospital, Fuzhou, Fujian, People's Republic of China.
概括
糖尿病药物利拉格卢提德改善了空间记忆,并减少了阿尔茨海默氏症的发生.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 生物化学 生化学
背景情况:
- 阿尔茨海默病 (AD) 是一种进展性神经退行性疾病,其全球流行率正在增加.
- 利拉格卢提德是一种用于2型糖尿病的葡萄糖类-1模拟物,在AD中显示出潜在的神经保护作用.
- 利拉格卢提德对阿尔茨海默病模型认知功能的影响需要进一步调查.
研究的目的:
- 在阿尔茨海默病的小鼠模型中评估利拉格卢提德对认知功能的影响.
- 调查由利拉格卢提德治疗影响的潜在机制,包括神经炎症和蛋白质表达.
主要方法:
- 治疗5×家族性阿尔茨海默病 (FAD) 的小鼠用利拉格卢提德治疗8周.
- 使用莫里斯水迷宫测试评估空间学习和记忆.
- 组织学分析 (尼斯尔染色,传输电子显微镜),神经炎症检测和蛋白质表达分析 (免疫组织化学,西方斑点).
主要成果:
- 在5×FAD小鼠中,利拉格卢提德的使用显著改善了空间认知能力.
- 治疗增加了金字塔细胞数量,缓解了突触超结构损伤,并减少了神经炎症.
- 利拉格卢提德降低了粉样β蛋白的表达,可能是通过调节NF-κB/BACE1通路.
结论:
- 利拉格卢提德在阿尔茨海默病小鼠模型中证明了提高认知功能的有效性.
- 治疗效益与降低神经炎症,改善突触完整性和降低粉胺β相关.
- 利拉格卢提德是一种有前途的药理策略,用于治疗像阿尔茨海默氏症这样的神经退行性疾病.
相关概念视频
01:22Alzheimer's Disease: Treatment
764
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
764
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
517
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
517
03:03Amyloid Fibrils
11.5K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
11.5K
03:03Amyloid Fibrils
6.3K
6.3K
01:24Glucagon-like Receptor Agonists
820
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
820